The neurovanguard concept and real-world embracement
Fabio Silvio Taccone, Edith Elianna Rodriguez, Mario Zaccarelli, Elda Diletta Sterchele

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsTraumatic Brain Injury and Neurovascular Disturbances · S100 Proteins and Annexins · Traumatic Brain Injury Research
Dear Editor,
We were delighted to receive the correspondence from Giglio et al. [1] regarding our recent viewpoint proposing the "NeuroVanguard" strategy for neuromonitoring in severe adult brain injury patients [2]. The authors aptly addressed potential challenges associated with implementing such an approach in real-world settings, particularly in low- and middle-income countries. These challenges include limited access to advanced invasive neuromonitoring modalities, such as intracranial pressure (ICP) monitoring, brain oxygenation assessment and metabolic monitoring. In these resource-constrained settings, reliance on clinical examination becomes paramount, along with the feasibility of assessing cerebral autoregulation at the bedside to guide therapeutic interventions, rather than solely focusing on brain compliance.
While we acknowledged the criticisms surrounding the use of ICP monitoring, particularly highlighted by the BEST-TRIP trial [3], several important points warrant attention. Firstly, it is noteworthy that less than 30% of patients in this trial exhibited elevated ICP. Consequently, the trial may not have been adequately identified the target population to demonstrate improved neurological outcomes with an ICP-guided therapy. Enhanced patient selection using non-invasive neuromonitoring modalities, such as cerebral ultrasound or automated pupillometry, could aid in screening individuals at high risk of intracranial hypertension. This targeted approach may justify the placement of an ICP monitor, even in resource-limited settings, where patients are most likely to benefit from ICP-guided therapy. Secondly, the BEST-TRIP trial revealed that patients undergoing ICP monitoring received less frequently therapies to reduce ICP, suggesting an overestimation or inaccuracy of clinical examination and brain imaging in identifying situations requiring such interventions. Lastly, in this study, there was a non-significant 5% increase in the proportion of patients with favorable outcomes in the ICP group; this raises the possibility that the study may have been underpowered to detect clinically relevant differences between the intervention arms.
We concur with the authors' perspective on the paramount importance of clinical examination as the primary neuromonitoring tool, underscoring its significance when conducted not only by physicians but notably by nurses. However, performing an adequate neurological examination in critically ill patients by non-neurologists may face several limitations, such as lack of expertise (e.g. leading to potential errors in assessment and interpretation), complexity of findings, presence of subtle symptoms (e.g. apraxia, dysgraphia), the presence of confounders (e.g. in particular the use of sedatives or intubation), and the lack of specialized equipments for some aspects of the neurological examination, such as cranial nerve function or reflexes. Moreover, most of non-neurologist healthcare providers present the so-called “neurophobia”, which refers to the fear or apprehension surrounding neurological examination and brain diseases due to the limited knowledge in this field [4]. Simplifying the neurological examination with specific scales like the Glasgow Coma Scale can pose challenges in accurately assessing neurological deterioration and determining appropriate therapeutic interventions in this context.
Finally, we respectfully disagree with the authors regarding the significance of cerebral autoregulation in guiding therapeutic interventions in the field of acute brain injured patients. While it has been suggested to elevate mean arterial pressure to potentially mitigate ICP surge in severe traumatic brain injury (TBI) patients, based on the efficacy of cerebral vasculature adjustment to pressure stimuli, the assessment of dynamic autoregulation poses challenges due to the variability in available indices and the requirement for specialized software and expertise [5], which may not be readily accessible in low- and middle-income countries. Furthermore, the intricate dynamics of cerebral autoregulation are influenced by factors such as metabolic activity, microcirculatory hematocrit, and perivascular pH, which cannot be adequately captured solely through pressure-autoregulation assessments. Consequently, while cerebral autoregulation monitoring shows promise in optimizing cerebral perfusion in TBI patients, its clinical applicability and feasibility require further validation across diverse patient populations and beyond specialized centers with extensive experience in neurocritical care.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Giglio A Pino M Ferre A Reccius A Adapting Neuro Vanguard to real-world challenges Crit Care 202428113710.1186/s 13054-024-04916-038654362 PMC 11040980 · doi ↗ · pubmed ↗
- 2Rodriguez EE Zaccarelli M Sterchele ED Taccone FS"Neuro Vanguard": a contemporary strategy in neuromonitoring for severe adult brain injury patients Crit Care 20242810410.1186/s 13054-024-04893-438561829 PMC 10985991 · doi ↗ · pubmed ↗
- 3Chesnut RM Temkin N Carney N Dikmen S Rondina C Videtta W Petroni G Lujan S Pridgeon J Barber J Machamer J Chaddock K Celix JM Cherner M Hendrix T Global Neurotrauma Research Group A trial of intracranial-pressure monitoring in traumatic brain injury N Engl J Med 2012367262471248110.1056/NEJ Moa 120736323234472 PMC 3565432 · doi ↗ · pubmed ↗
- 4Jozefowicz RF Neurophobia: the fear of neurology among medical students Arch Neurol 199451432832910.1001/archneur.1994.005401600180038155008 · doi ↗ · pubmed ↗
- 5Burma JS, Roy MA, Kennedy CM, Labrecque L, Brassard P, Smirl JD. A systematic review, meta-analysis, and meta-regression amalgamating the driven approaches used to quantify dynamic cerebral autoregulation. J Cereb Blood Flow Metab. 2024: 271678 X 24123587810.1177/0271678 X 241235878 PMC 1134273138635887 · doi ↗ · pubmed ↗
